A CanSino Biologics employee works on the production of the recombinant Covid-19 vaccine in September. Photo: Getty Images
CanSino Biologics CEO Yu Xuefeng says mRNA vaccines are key to China’s coronavirus fight
- China has yet to approve any mRNA vaccines, which have a much higher efficacy rate than ones made using older forms of technology
- CanSino Biologics has started a clinical trial in Beijing, and the World Health Organization has approved its viral vector vaccine for emergency use
Follow your favourite topic and get notified
A CanSino Biologics employee works on the production of the recombinant Covid-19 vaccine in September. Photo: Getty Images